NCT04709458Source recordAI-normalized
A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis
Taiga Biotechnologies, Inc. is advancing TBX-2400 through a Phase 1 clinical trial aimed at improving outcomes for patients undergoing allogeneic stem cell transplantation for Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF). The potential to shorten the time to immune reconstitution could position TBX-2400 favorably in a market characterized by high unmet needs in hematologic malignancies. The competitive landscape includes established therapies and emerging candidates targeting similar patient populations. Successful trial outcomes could enhance Taiga's market position and attract partnerships or acquisition interest, given the growing focus on innovative therapies in oncology.
AI analysis
Indication: Myelofibrosis
Modality: protein therapy
Target: TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.
Sponsor: Taiga Biotechnologies, Inc.
Source URL: ClinicalTrials.gov
Source updated: May 03, 2022
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Myelofibrosis, Acute Myelogenous Leukemia
Condition normalized: Myelofibrosis, Acute Myelogenous Leukemia
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.
Target normalized: TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.
NCT01520558Source recordAI-normalized
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
The clinical trial for CNDO-109-Activated Allogeneic Natural Killer Cells targets high-risk acute myeloid leukemia (AML) patients in their first complete remission who are not candidates for stem cell transplantation. Given the high unmet medical need in this patient population, successful outcomes could position Coronado Biosciences favorably in the oncology market, particularly in the immunotherapy segment. The competitive landscape includes other immunotherapeutic approaches for AML, necessitating a thorough assessment of efficacy and safety to differentiate CNDO-109 from existing therapies. Diligence should focus on regulatory pathways and potential partnerships for commercialization, especially considering the trial's non-randomized design and the limited patient enrollment (12 participants).
AI analysis
Indication: Acute Myeloid Leukemia
Modality: protein therapy
Target: CNDO-109-Activated Allogeneic Natural Killer Cells
Sponsor: Coronado Biosciences, Inc.
Source URL: ClinicalTrials.gov
Source updated: Jun 29, 2017
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Acute Myeloid Leukemia
Condition normalized: Acute Myeloid Leukemia
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CNDO-109-Activated Allogeneic Natural Killer Cells
Target normalized: CNDO-109-Activated Allogeneic Natural Killer Cells
NCT06620302Source recordAI-normalized
DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma
The trial is sponsored by the Children's Oncology Group and aims to evaluate the safety and efficacy of DT2216 in combination with irinotecan for treating relapsed or refractory solid tumors, particularly fibrolamellar carcinoma (FLC) in pediatric and young adult populations. Given the limited treatment options for these patient groups, successful outcomes could position DT2216 as a novel therapeutic option, potentially capturing a niche market in pediatric oncology. The combination therapy may also enhance the competitive landscape against existing treatments, particularly for FLC, which has a unique molecular profile. The trial's focus on a specific genetic marker (DNAJB1:PRKACA fusion) in FLC could provide a targeted approach, appealing to precision medicine strategies in oncology. Stakeholders should monitor the trial's progress closely for potential partnership or acquisition opportunities, especially if early results indicate significant efficacy.
AI analysis
Indication: Childhood Fibrolamellar Carcinoma
Modality: protein therapy
Target: Bcl-xL (B-cell lymphoma-extra large) protein, a key anti-apoptotic protein involved in tumor cell survival.
Sponsor: Children's Oncology Group
Source URL: ClinicalTrials.gov
Source updated: May 05, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Childhood Fibrolamellar Carcinoma, Refractory Childhood Malignant Solid Neoplasm, Refractory Fibrolamellar Carcinoma, Refractory Malignant Solid Neoplasm
Condition normalized: Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Childhood Fibrolamellar Carcinoma, Refractory Childhood Malignant Solid Neoplasm, Refractory Fibrolamellar Carcinoma, Refractory Malignant Solid Neoplasm
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Bcl-xL (B-cell lymphoma-extra large) protein, a key anti-apoptotic protein involved in tumor cell survival.
Target normalized: Bcl-xL (B-cell lymphoma-extra large) protein, a key anti-apoptotic protein involved in tumor cell survival.
NCT05168709Source recordAI-normalized
A Single-arm Clinical Trial to Investigate COVID-19 Specific Vaccine and Heterologous Immunity in the Melbourne Infant Study of BCG for Allergy and Infection Reduction (COSI BAIR)
The COSI BAIR trial, sponsored by the Murdoch Childrens Research Institute, focuses on the effects of the COVID-19 vaccine on immunity in children aged 5 to 8 years. With a completion date of September 2022, the study aims to elucidate the specific and heterologous effects of COVID-19 vaccination, potentially influencing future pediatric vaccination strategies. The findings may enhance the understanding of vaccine responses in children, providing a competitive edge in the pediatric vaccine market, especially in the context of ongoing global vaccination efforts against COVID-19. Given the increasing focus on vaccine safety and efficacy in younger populations, the results could have significant implications for public health policies and vaccine development strategies.
AI analysis
Indication: COVID-19
Modality: protein therapy
Target: COVID-19 specific immunity and heterologous immunity mechanisms in children
Sponsor: Murdoch Childrens Research Institute
Source URL: ClinicalTrials.gov
Source updated: Feb 09, 2023
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: COVID-19, Vaccine Reaction, Immunization; Infection
Condition normalized: COVID-19, Vaccine Reaction, Immunization; Infection
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: COVID-19 specific immunity and heterologous immunity mechanisms in children
Target normalized: COVID-19 specific immunity and heterologous immunity mechanisms in children
NCT05631912Source recordAI-normalized
Autologous TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor T (STAR-T) Cells for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
The clinical trial is sponsored by the Chinese PLA General Hospital and aims to evaluate the safety and efficacy of autologous CD19-targeting STAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL). Given the increasing prevalence of B-NHL and the limitations of existing CAR-T therapies, this innovative approach may provide a competitive edge in the CAR-T market. The trial's focus on a novel mechanism that potentially reduces toxicity while maintaining efficacy could attract interest from investors and pharmaceutical companies looking to expand their oncology portfolios. The estimated patient enrollment of 19 to 38 suggests a targeted approach that may facilitate rapid data collection and analysis, enhancing the asset's attractiveness for future partnerships or acquisitions.
AI analysis
Indication: Non-hodgkin Lymphoma,B Cell
Modality: protein therapy
Target: CD19-targeting synthetic T-cell receptor (STAR) utilizing CRISPR/Cas9 technology to disrupt the TRAC locus for enhanced T-cell therapy.
Sponsor: Chinese PLA General Hospital
Source URL: ClinicalTrials.gov
Source updated: Jul 06, 2023
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Non-hodgkin Lymphoma,B Cell
Condition normalized: Non-hodgkin Lymphoma,B Cell
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD19-targeting synthetic T-cell receptor (STAR) utilizing CRISPR/Cas9 technology to disrupt the TRAC locus for enhanced T-cell therapy.
Target normalized: CD19-targeting synthetic T-cell receptor (STAR) utilizing CRISPR/Cas9 technology to disrupt the TRAC locus for enhanced T-cell therapy.
NCT06838832Source recordAI-normalized
Novel Allogenic CD19-targeting Chimeric Antigen Receptor γδT Cells Therapy (QH103E) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
The QH103E therapy represents a novel approach in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) by utilizing allogeneic γδT cells engineered to express a CD19-targeting CAR. The market for CAR T-cell therapies is rapidly expanding, with significant demand for innovative treatments in hematological malignancies. Given the increasing prevalence of NHL and the limitations of existing therapies, QH103E could capture a substantial share of this market if proven effective and safe. Competitive analysis indicates that while there are established players in the CAR T-cell space, the unique mechanism of action and potential for enhanced memory efficacy may provide a differentiated position. Diligence should focus on the regulatory pathway, potential partnerships, and reimbursement strategies, particularly in the context of the Chinese healthcare system.
AI analysis
Indication: Non-hodgkin Lymphoma,B Cell
Modality: protein therapy
Target: CD19-targeting Chimeric Antigen Receptor (CAR) on allogeneic γδT cells
Sponsor: Chinese PLA General Hospital
Source URL: ClinicalTrials.gov
Source updated: Jul 30, 2025
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Non-hodgkin Lymphoma,B Cell
Condition normalized: Non-hodgkin Lymphoma,B Cell
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD19-targeting Chimeric Antigen Receptor (CAR) on allogeneic γδT cells
Target normalized: CD19-targeting Chimeric Antigen Receptor (CAR) on allogeneic γδT cells
NCT05946226Source recordAI-normalized
A Phase I, Open-label, Multi-center, Dose-escalation Study to Evaluate the Safety, Feasibility, and Preliminary Efficacy of IMC002 in Patients With Claudin18.2-positive Advanced Digestive System Tumors
IMC002 is being developed by Suzhou Immunofoco Biotechnology Co., Ltd as a potential treatment for advanced digestive system tumors that express CLDN18.2, including gastric and pancreatic cancers. The market for targeted therapies in these indications is significant, given the high unmet need and the limitations of current standard-of-care treatments. The competitive landscape includes other CAR-T therapies targeting similar antigens, necessitating a robust differentiation strategy based on safety and efficacy profiles. The trial's focus on a specific biomarker (CLDN18.2) may enhance patient selection and improve treatment outcomes, potentially leading to a favorable market position if successful. Diligence should focus on regulatory pathways, especially given the complexities associated with CAR-T therapies, and the need for comprehensive safety data to support future commercialization efforts.
AI analysis
Indication: Advanced Digestive System Tumor
Modality: protein therapy
Target: Claudin 18.2 (CLDN18.2)
Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd
Source URL: ClinicalTrials.gov
Source updated: Sep 28, 2023
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Advanced Digestive System Tumor
Condition normalized: Advanced Digestive System Tumor
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Claudin 18.2 (CLDN18.2)
Target normalized: Claudin 18.2 (CLDN18.2)
NCT06154252Source recordAI-normalized
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Cabaletta Bio's CABA-201 is positioned to address a significant unmet need in the treatment of Idiopathic Inflammatory Myopathy (IIM), including its juvenile form. The market for IIM therapies is currently underserved, with limited effective options available. The successful development of CABA-201 could provide a first-in-class treatment, potentially capturing a substantial share of the market. Given the increasing prevalence of autoimmune diseases and the growing interest in CAR T-cell therapies, this asset may attract significant attention from investors and partners. Competitive analysis indicates that while there are existing therapies for IIM, none specifically target the underlying mechanisms of disease as CABA-201 aims to do, positioning it favorably against current treatments.
AI analysis
Indication: Idiopathic Inflammatory Myopathy
Modality: protein therapy
Target: CD19-specific Chimeric Antigen Receptor T Cells (CABA-201)
Sponsor: Cabaletta Bio
Source URL: ClinicalTrials.gov
Source updated: Jun 10, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Condition normalized: Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD19-specific Chimeric Antigen Receptor T Cells (CABA-201)
Target normalized: CD19-specific Chimeric Antigen Receptor T Cells (CABA-201)
NCT04362826Source recordAI-normalized
A Randomized, Double-blind, Placebo Controlled, Parallel Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer Patients
The study, sponsored by Case Comprehensive Cancer Center, aims to evaluate the efficacy of BIOHM, a novel probiotic, in altering the microbiome profiles of breast cancer patients. Given the increasing interest in the role of the microbiome in cancer treatment and prevention, successful outcomes could position BIOHM as a complementary therapy in breast cancer management. The market for probiotics is growing, with a focus on personalized medicine and microbiome research. If proven effective, this could lead to significant commercial opportunities for BIOHM Health LLC, particularly in oncology. The competitive landscape includes other microbiome-focused therapies, necessitating a robust differentiation strategy. Due diligence should consider regulatory pathways, potential market access challenges, and the need for further studies to establish clinical utility.
AI analysis
Indication: Breast Cancer
Modality: protein therapy
Target: Bacteriome and Mycobiome modulation in breast cancer patients
Sponsor: Case Comprehensive Cancer Center
Source URL: ClinicalTrials.gov
Source updated: Apr 09, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Bacteriome and Mycobiome modulation in breast cancer patients
Target normalized: Bacteriome and Mycobiome modulation in breast cancer patients
NCT04554940Source recordAI-normalized
A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression Surgery
Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery
AI analysis
Indication: Achondroplasia
Modality: protein therapy
Target: vosoritide
Sponsor: BioMarin Pharmaceutical
Source URL: ClinicalTrials.gov
Source updated: Mar 13, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: vosoritide
Target normalized: vosoritide
NCT05569356Source recordAI-normalized
Biomarkers of Inflammation and Autoimmunity: Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy.
This study aims to identify novel inflammatory biomarkers in AC, whether in circulating blood, in situ or as imaging biomarkers to better understand the pathophysiology of the disease and then to determine contribution to the clinical management of patients.
AI analysis
Indication: Arrhythmogenic Cardiomyopathy
Modality: protein therapy
Target: Prospective, Retrospective
Sponsor: Assistance Publique - Hôpitaux de Paris
Source URL: ClinicalTrials.gov
Source updated: Oct 13, 2022
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Arrhythmogenic Cardiomyopathy
Condition normalized: Arrhythmogenic Cardiomyopathy
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Prospective, Retrospective
Target normalized: Prospective, Retrospective
NCT05352516Source recordAI-normalized
A Randomized, Double-Blind, International Multicentre, Parallel-Controlled Phase III Clinical Study to Evaluate Recombinant Anti-RANKL Human Monoclonal Antibody Injection (HLX14) Versus Denosumab Injection (Prolia®) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
This is a randomized, double-blind, international multicentre, parallel-controlled phase III clinical study. The study plans to enroll 478 postmenopausal women with osteoporosis at high risk of fracture, whom will be randomized at 1:1 to either the experiment group (HLX14) or the control group (Prolia®) based on stratification factors (BMI (\< 25, 25-30, \> 30) and geographic region (Asian or non-Asian)). The study includes screening period (28 days), treatment period (total 546 days, contain treatment period 1: D1-D364, treatment period 2: D365-D546), and an end-of-study visit (D547).
AI analysis
Indication: Postmenopausal
Modality: protein therapy
Target: HLX14, Prolia®
Sponsor: Shanghai Henlius Biotech
Source URL: ClinicalTrials.gov
Source updated: Sep 20, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Postmenopausal
Condition normalized: Postmenopausal
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: HLX14, Prolia®
Target normalized: HLX14, Prolia®
NCT00357760Source recordAI-normalized
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
This randomized phase II trial studies how well ziv-aflibercept (VEGF Trap) works in treating patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) or is unable to be removed with surgery (unresectable). Ziv-aflibercept may stop the growth of kidney cancer by blocking blood flow to the tumor.
AI analysis
Indication: Metastatic Renal Cell Carcinoma
Modality: protein therapy
Target: VEGF Trap
Sponsor: National Cancer Institute (NCI)
Source URL: ClinicalTrials.gov
Source updated: Jun 23, 2017
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Metastatic Renal Cell Carcinoma
Condition normalized: Metastatic Renal Cell Carcinoma
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: VEGF Trap
Target normalized: VEGF Trap
NCT07360691Source recordAI-normalized
Early Clinical Outcomes of High-Purity Type I Collagen as a Biologic Reinforcement in Selected Hernia Repair Scenarios: A Prospective Clinical Study
This prospective, single-arm clinical study evaluates the safety, feasibility, and early clinical outcomes of High-Purity Type I Collagen (HPTC; Surgicoll-Mesh®) when used as a biologic reinforcement in selected hernia repair scenarios where permanent synthetic mesh placement is undesirable. Outcomes focus on early postoperative safety, wound healing, and complication profiles over an 8-week follow-up period.
AI analysis
Indication: Hernia
Modality: protein therapy
Target: High-Purity Type I Collagen Mesh
Sponsor: Adichunchanagiri Institute of Medical Sciences, B G Nagara
Source URL: ClinicalTrials.gov
Source updated: Apr 23, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Hernia, Ventral Hernia, Incisional Hernia, İnguinal Hernia, Abdominal Wall Hernia, Surgical Site Infection, Postoperative Complications
Condition normalized: Hernia, Ventral Hernia, Incisional Hernia, İnguinal Hernia, Abdominal Wall Hernia, Surgical Site Infection, Postoperative Complications
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: High-Purity Type I Collagen Mesh
Target normalized: High-Purity Type I Collagen Mesh
NCT00187018Source recordAI-normalized
Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study
Osteogenesis imperfecta (OI) is a genetic disease for which there is currently no known cure. OI causes the osteoblasts (bone-forming cells in the body) to grow poorly, which slows the growth of children with the disease and causes their bones to bend and break easily. Some forms of osteogenesis imperfecta may cause severe disability and even death. In previous research studies performed at St. Jude, it was found that children treated with bone marrow transplant (infusion of healthy immature blood-forming cells) began to grow faster, had more minerals (material that helps make the bones strong) in their bones, and broke their bones less often than before the bone marrow transplant. Several months after the bone marrow transplant however, body growth once again began to slow down. In this research study, children with osteogenesis imperfecta will receive another infusion of bone marrow cells but without any chemotherapy. The marrow cells will come from the same bone marrow donor as their previous bone marrow transplant. It is hoped that by removing the CD3+ cells (a type of white blood cells that attack other cells that are not like themselves) from the donated bone marrow, the subject's body will be infused quite safely and that body growth and bone strength will increase. The CD3+ cells will be removed from the donor bone marrow by use of a machine called the CliniMACS System. This machine has not been approved for use in the United States by the Food and Drug Administration (FDA). The use of this device is considered experimental.
AI analysis
Indication: Osteogenesis Imperfecta
Modality: protein therapy
Target: Bone marrow transplant
Sponsor: St. Jude Children's Research Hospital
Source URL: ClinicalTrials.gov
Source updated: Mar 04, 2015
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Bone marrow transplant
Target normalized: Bone marrow transplant
NCT05043311Source recordAI-normalized
A Randomized, Double-blinded, Placebo-controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA Vaccine Against COVID-19.
The objective of this study is to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.
AI analysis
Indication: COVID-19
Modality: protein therapy
Target: SCTV01C, Placebo
Sponsor: Sinocelltech Ltd.
Source URL: ClinicalTrials.gov
Source updated: Jan 25, 2022
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: COVID-19, SARS-CoV-2 Infection
Condition normalized: COVID-19, SARS-CoV-2 Infection
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: SCTV01C, Placebo
Target normalized: SCTV01C, Placebo
NCT04992247Source recordAI-normalized
A Phase 2A Randomized, Placebo-Controlled Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.
AI analysis
Indication: Covid19
Modality: protein therapy
Target: COVI-MSC, Placebo
Sponsor: Sorrento Therapeutics, Inc.
Source URL: ClinicalTrials.gov
Source updated: Apr 17, 2024
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Covid19
Condition normalized: Covid19
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: COVI-MSC, Placebo
Target normalized: COVI-MSC, Placebo
NCT07480811Source recordAI-normalized
The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD
The clinical trial sponsored by Antalya Training and Research Hospital aims to evaluate the efficacy of the DASH diet in managing MASLD in children aged 11-18 years. Given the rising prevalence of MASLD alongside childhood obesity, this study addresses a significant unmet medical need. The market for pediatric liver disease management is expanding, particularly as awareness of non-alcoholic fatty liver disease grows. The trial's focus on dietary interventions may position it favorably against pharmacological approaches, which are currently limited. Successful outcomes could lead to the establishment of dietary guidelines and interventions that could be monetized through partnerships with healthcare providers and nutrition-focused organizations.
AI analysis
Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Modality: protein therapy
Target: Dietary modification focusing on anti-inflammatory and antioxidant properties to improve metabolic health in pediatric patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Sponsor: Antalya Training and Research Hospital
Source URL: ClinicalTrials.gov
Source updated: Mar 18, 2026
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Condition normalized: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Dietary modification focusing on anti-inflammatory and antioxidant properties to improve metabolic health in pediatric patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Target normalized: Dietary modification focusing on anti-inflammatory and antioxidant properties to improve metabolic health in pediatric patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
NCT01127035Source recordAI-normalized
STUDIO IN DOPPIO CIECO DISODIOCROMOGLICATO + PLACEBO vs DISODIOCROMOGLICATO + IMMUNOTERAPIA SPECIFICA SUBLINGUALE PER ALTERNARIA IN PAZIENTI CON RINITE ALLERGICA DOVUTA A SENSIBILIZZAZIONE AD ALTERNARIA
Respiratory allergy due to Alternaria is a relevant clinical problem, and specific immunotherapy may represent a viable treatment option. Sublingual immunotherapy (SLIT) is safe and effective, but data for Alternaria are lacking. The study is aimed at assessing the efficacy of a standardized SLIT in patients sensitised to Alternaria, in a randomized, double blind, placebo controlled fashion. Patients with rhinitis with/without intermittent asthma, and ascertained allergy to Alternaria are enrolled. After a baseline season, SLIT or matched placebo are given for 10 months. Symptoms and rescue medication intake are recorded on diary cards from June to October. Skin prick test, specific IgE and IgG4 and precipitins are measured at baseline and at the end of the study. Alternaria spore count is also performed. Primary outcome is the change in symptom score in the active vs placebo group. Secondary outcomes: changes in rescue medication intake, alternaria specific IgE and IgG4, skin prick test reactivity.
AI analysis
Indication: Allergic Rhinitis (w/w Asthma) Due to Alternaria Alternata
Modality: protein therapy
Target: sublingual immunotherapy, placebo
Sponsor: University of Genova
Source URL: ClinicalTrials.gov
Source updated: Jun 07, 2010
Ingested: Jun 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Allergic Rhinitis (w/w Asthma) Due to Alternaria Alternata
Condition normalized: Allergic Rhinitis (w/w Asthma) Due to Alternaria Alternata
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: sublingual immunotherapy, placebo
Target normalized: sublingual immunotherapy, placebo
NCT06943677Source recordAI-normalized
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsules in Subjects With Advanced Malignant Tumors
The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3019 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3019 capsules.
AI analysis
Indication: Advanced Malignant Cancer
Modality: protein therapy
Target: TQB3019 capsules
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Feb 12, 2026
Ingested: Jun 05, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Advanced Malignant Cancer
Condition normalized: Advanced Malignant Cancer
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: TQB3019 capsules
Target normalized: TQB3019 capsules
NCT02385006Source recordAI-normalized
Thromboelastographic Profile During Simultaneous Pancreas-kidney Transplantation
This study evaluates the efficacy of thromboelastography (ROTEM®) in detecting coagulation disorders during simultaneous pancreas-kidney transplantation compared to kidney-only transplantation. Conducted by Hospices Civils de Lyon, the study involved 152 participants over a 36-month period.
AI analysis
Indication: Blood Coagulation
Modality: protein therapy
Target: Blood Coagulation Disorders in Pancreas-Kidney Transplantation
Sponsor: Hospices Civils de Lyon
Source URL: ClinicalTrials.gov
Source updated: Mar 11, 2015
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Blood Coagulation
Condition normalized: Blood Coagulation
Modality raw: Blood Coagulation
Modality normalized: protein therapy
Target raw: Blood Coagulation Disorders in Pancreas-Kidney Transplantation
Target normalized: Blood Coagulation Disorders in Pancreas-Kidney Transplantation
NCT04916067Source recordAI-normalized
Stoma Closure and Reinforcement (SCAR)-II Trial: A Single Center Pilot Study of the Safety of a Mesh Reinforcement of Ileostomy Closure to Prevent Hernia Formation in Inflammatory Bowel Disease Patients
The SCAR-II trial aimed to evaluate the safety and effectiveness of a bioresorbable mesh reinforcement technique during ileostomy closure in patients with inflammatory bowel disease. The study was conducted at Dartmouth-Hitchcock Medical Center but was terminated early due to resource constraints, with only 8 participants enrolled.
AI analysis
Indication: Ileostomy - Stoma
Modality: protein therapy
Target: Hernia formation prevention in ileostomy closure
Sponsor: Dartmouth-Hitchcock Medical Center
Source URL: ClinicalTrials.gov
Source updated: Feb 27, 2026
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Ileostomy - Stoma
Condition normalized: Ileostomy - Stoma
Modality raw: Ileostomy - Stoma
Modality normalized: protein therapy
Target raw: Hernia formation prevention in ileostomy closure
Target normalized: Hernia formation prevention in ileostomy closure
NCT03959722Source recordAI-normalized
The Effect of Probiotics on the Relationship Between the Gut Microbiota and Gastrointestinal Symptoms During Endurance Exercise'
This completed clinical trial investigated the effect of probiotics on gastrointestinal symptoms and performance in trained male endurance athletes. The study involved a double-blind, randomized, placebo-controlled design with 42 participants over a 14-week supplementation period using Ecologic® PERFORMANCE probiotics.
AI analysis
Indication: Gastrointestinal Symptoms
Modality: protein therapy
Target: Gastrointestinal Symptoms in Endurance Athletes
Sponsor: Karlijn te Poele
Source URL: ClinicalTrials.gov
Source updated: Sep 09, 2020
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Gastrointestinal Symptoms
Condition normalized: Gastrointestinal Symptoms
Modality raw: Gastrointestinal Symptoms
Modality normalized: protein therapy
Target raw: Gastrointestinal Symptoms in Endurance Athletes
Target normalized: Gastrointestinal Symptoms in Endurance Athletes
NCT00849524Source recordAI-normalized
A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
The trial aimed to evaluate the safety and efficacy of Ad-ISF35, a cancer vaccine, administered via intranodal injection in patients with CLL/SLL. The study was conducted at the University of California, San Diego, with a total enrollment of 6 participants.
AI analysis
Indication: Chronic Lymphocytic Leukemia
Modality: protein therapy
Target: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Sponsor: Januario Castro, M.D.
Source URL: ClinicalTrials.gov
Source updated: Dec 30, 2015
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Chronic Lymphocytic Leukemia
Condition normalized: Chronic Lymphocytic Leukemia
Modality raw: Chronic Lymphocytic Leukemia
Modality normalized: protein therapy
Target raw: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Target normalized: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04842682Source recordAI-normalized
A Phase I Multicenter Double-blind Placebo Controlled Dose Escalation Trial of an Adjuvanted Anti-CD40 mAb Fused to Env GP140 HIV Clade C ZM-96 (CD40.HIVRI.Env) Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Participants
The trial evaluates the safety and immunogenicity of the CD40.HIVRI.Env vaccine, both alone and in combination with the DNA-HIV-PT123 vaccine, in healthy volunteers. Conducted in France and Switzerland, it aims to establish a dose escalation strategy with a total enrollment of 72 participants. The study is sponsored by ANRS, Emerging Infectious Diseases.
AI analysis
Indication: Healthy Adults
Modality: protein therapy
Target: HIV-1 Vaccine
Sponsor: ANRS, Emerging Infectious Diseases
Source URL: ClinicalTrials.gov
Source updated: Dec 17, 2024
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Healthy Adults
Condition normalized: Healthy Adults
Modality raw: Healthy Adults
Modality normalized: protein therapy
Target raw: HIV-1 Vaccine
Target normalized: HIV-1 Vaccine
NCT04542941Source recordAI-normalized
Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial
Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial is a NA clinical asset sponsored by Makerere University in Covid19. SEO and diligence focus: COVID Convalescent Plasma, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Covid19
Modality: protein therapy
Target: COVID Convalescent Plasma
Sponsor: Makerere University
Source URL: ClinicalTrials.gov
Source updated: Jan 15, 2021
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Covid19
Condition normalized: Covid19
Modality raw: COVID antiviral
Modality normalized: protein therapy
Target raw: COVID Convalescent Plasma
Target normalized: COVID Convalescent Plasma
NCT06318169Source recordAI-normalized
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis is a PHASE3 clinical asset sponsored by 89bio, Inc. in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis. SEO and diligence focus: Pegozafermin, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Modality: protein therapy
Target: Pegozafermin, Placebo
Sponsor: 89bio, Inc.
Source URL: ClinicalTrials.gov
Source updated: Jun 04, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Condition normalized: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Pegozafermin, Placebo
Target normalized: Pegozafermin, Placebo
NCT03989505Source recordAI-normalized
Proenkephalin ANd Creatinine in the Prediction of Cardiac Contrast-Associated Kidney Events
Currently, contrast-induced kidney injury cannot be diagnosed on the day of cardiac catheterization. Recently, proenkephalin (penKid) was introduced as a new glomerular filtration marker. The aim of this study is to investigate whether the change in penKid level allows for early detection of affected patients.
AI analysis
Indication: Contrast-induced Nephropathy
Modality: protein therapy
Target: blood-draw for biomarker analyses
Sponsor: Dr. med. Mahir Karakas
Source URL: ClinicalTrials.gov
Source updated: May 18, 2022
Ingested: May 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: protein therapy
View original source fields
Condition raw: Contrast-induced Nephropathy, Acute Kidney Injury, Coronary Artery Disease
Condition normalized: Contrast-induced Nephropathy, Acute Kidney Injury, Coronary Artery Disease
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: blood-draw for biomarker analyses
Target normalized: blood-draw for biomarker analyses